Cargando…
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
Low-molecular weight chemical compounds have a longstanding history as drugs. Target specificity and binding efficiency represent major obstacles for small molecules to become clinically relevant. Protein kinases are attractive cellular targets; however, they are challenging because they present one...
Autores principales: | Zain, Rula, Vihinen, Mauno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328433/ https://www.ncbi.nlm.nih.gov/pubmed/34349760 http://dx.doi.org/10.3389/fimmu.2021.694853 |
Ejemplares similares
-
Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
por: Lewis, Katharine L, et al.
Publicado: (2021) -
Discovery of a Potent, Covalent BTK Inhibitor for
B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014) -
PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023) -
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021) -
A covalent BTK ternary complex compatible with targeted protein degradation
por: Schiemer, James, et al.
Publicado: (2023)